Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.935 USD | -2.06% | -8.46% | -48.15% |
Financials (USD)
Sales 2024 * | 410M | Sales 2025 * | 465M | Capitalization | 963M |
---|---|---|---|---|---|
Net income 2024 * | 63M | Net income 2025 * | 99M | EV / Sales 2024 * | 2.35 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.07 x |
P/E ratio 2024 * |
12.1
x | P/E ratio 2025 * |
7.74
x | Employees | 267 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.33% |
Latest transcript on Ironwood Pharmaceuticals, Inc.
1 day | -6.63% | ||
1 week | -8.73% | ||
Current month | -21.81% | ||
1 month | -27.08% | ||
3 months | -59.79% | ||
6 months | -36.14% | ||
Current year | -47.03% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas McCourt
CEO | Chief Executive Officer | 66 | 08-12-31 |
Sravan Emany
DFI | Director of Finance/CFO | 46 | 21-12-05 |
Marcel Moulaison
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alexander Denner
BRD | Director/Board Member | 54 | 20-11-08 |
Jay Shepard
BRD | Director/Board Member | 65 | 20-12-02 |
Mark Currie
BRD | Director/Board Member | 69 | 19-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.50% | 28 M€ | -2.47% | ||
0.42% | 25 M€ | -3.35% | - | |
0.35% | 1,085 M€ | +7.91% | - | |
0.20% | 43 M€ | +2.40% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 5.945 | -1.90% | 1 207 812 |
24-05-23 | 6.06 | -6.63% | 2,612,457 |
24-05-22 | 6.49 | -4.28% | 2,287,825 |
24-05-21 | 6.78 | +5.61% | 2,315,775 |
24-05-20 | 6.42 | -0.93% | 2,127,427 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.03% | 963M | |
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+44.76% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |
- Stock Market
- Equities
- IRWD Stock